Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 10/20 | 0.42 |
| ▸ | ITGA2B | P08514 | 10/20 | 0.42 |
| ▸ | TGM2 | P21980 | 4/20 | 0.41 |
| ▸ | F13A1 | P00488 | 1/20 | 0.41 |
| ▸ | TGM1 | P22735 | 1/20 | 0.41 |
| ▸ | P2RY12 | Q9H244 | 4/20 | 0.37 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13498637 | 0.90 | ITGB3 (0.42) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL13711557 | 0.80 | TGM2 (0.45) | TGM2F13A1TGM1 | |
| SCHEMBL14445101 | 0.78 | TGM2 (0.41) | TGM2F13A1TGM1 | |
| SCHEMBL13671325 | 0.77 | MEN1 (0.50) | ITGB3ITGA2BTGM2 | |
| SCHEMBL13674663 | 0.76 | TGM2 (0.43) | ITGB3ITGA2BTGM2F13A1TGM1 | |
| SCHEMBL13674476 | 0.73 | ACHE (0.43) | TGM2F13A1TGM1 | |
| SCHEMBL13674472 | 0.73 | TGM2 (0.46) | TGM2F13A1TGM1 | |
| SCHEMBL14262320 | 0.72 | SIRT1 (0.44) | — | |
| SCHEMBL13674665 | 0.70 | TGM2 (0.43) | TGM2F13A1TGM1P2RY12 | |
| SCHEMBL25176384 | 0.69 | EPHX1 (0.50) | TGM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | NOVO NORDISK A/S (DK) | 2016-12-08 | — | — | US | disclosed |
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | NOVO NORDISK HEALTHCARE AG (CH) | 2014-09-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140274903-A1 | USE OF GALACTOSE OXIDASE FOR SELECTIVE CHEMICAL CONJUGATION OF PROTRACTOR MOLECULES TO PROTEINS OF THERAPEUTIC INTEREST | GALE, GALNT2, GALNT1 | ITGB3 380/4885ITGA2B 420/4885TGM2 102/4885 |
| US-20160355859-A1 | TRANSGLUTAMINASE MEDIATED CONJUGATION OF PEPTIDES | TGM2, TGM3, TGM1 | ITGB3 2477/4885ITGA2B 2137/4885TGM2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.